Thu, November 17, 2022
Wed, November 16, 2022
Tue, November 15, 2022
Mon, November 14, 2022
Fri, November 11, 2022

Judah Frommer Maintained (ABOS) at Buy with Decreased Target to $16 on, Nov 15th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-16-on-nov-15th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Judah Frommer of Credit Suisse, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Buy with Decreased Target from $17 to $16 on, Nov 15th, 2022.

Judah has made no other calls on ABOS in the last 4 months.



There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Judah's Rating of Hold.



This is the rating of the analyst that currently disagrees with Judah


  • Thomas Shrader of "BTIG" Maintained at Strong Buy with Increased Target to $22 on, Wednesday, October 5th, 2022

Publication Contributing Sources